- Home
- BYSI
BYSI
BeyondSpring Inc.
as 09-18-2025 4:00pm EST
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 73.4M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 22.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $3.44 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of BeyondSpring Inc. (BYSI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 16 '25 | Sell | $1.88 | 840 | $1,579.20 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 15 '25 | Sell | $1.84 | 2,570 | $4,728.80 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 12 '25 | Sell | $1.85 | 700 | $1,295.00 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 11 '25 | Sell | $1.90 | 3,820 | $7,258.00 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 10 '25 | Sell | $1.93 | 8,176 | $15,779.68 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 9 '25 | Sell | $1.97 | 9,050 | $17,828.50 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 8 '25 | Sell | $1.93 | 7,090 | $13,683.70 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 5 '25 | Sell | $1.86 | 1,106 | $2,057.16 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 4 '25 | Sell | $1.82 | 803 | $1,461.46 | 1,870,600 | |
| Decheng Capital China Life Sciences USD Fund III, L.P. | BYSI | 10% Owner | Sep 3 '25 | Sell | $1.81 | 1,270 | $2,298.70 | 1,870,600 |
Latest BeyondSpring Inc. News
BYSI Breaking Stock News: Dive into BYSI Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 months ago
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
GlobeNewswire
4 months ago
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Simply Wall St.
4 months ago
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
GlobeNewswire
4 months ago
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
6 months ago
BeyondSpring Files 2024 Annual Report on Form 10-K
GlobeNewswire
6 months ago
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
GlobeNewswire
8 months ago
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
GlobeNewswire
8 months ago
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Compare BYSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BYSI BeyondSpring Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.